The Kidney Cancer Association Appoints Kendall Monroe as CAO
HOUSTON– March 19, 2019– The Kidney Cancer Association (KCA) is pleased to announce that Kendall Monroe has joined the organization as its first Chief Advancement Officer (CAO). Monroe brings more than a decade of experience in development, fundraising and donor relations. Monroe most recently worked as the director of planned giving and board management with the University of St. Thomas. She previously held several positions within MD Anderson Cancer Center - including assistant director of development, associate director of development and director of trusts, estates and gift planning. Additional roles i...
Source: Kidney Cancer Association - March 21, 2019 Category: Urology & Nephrology Source Type: news

Joanne battles stage 4 kidney cancer
Four years ago, Joanne Romero, who lives in Texas, was diagnosed with stage 4 kidney cancer when she was 26 weeks pregnant. Despite her challenges, Joanne remains positive and hopes her story serves as an inspiration to others.   My journey began on Feb. 16, 2015. I was currently 26 weeks pregnant. I was experiencing a cough that continued to get worse. That day, I was scheduled to have a lung procedure to see what was causing the cough. My high-risk OB ordered an ultrasound the night before. She wanted to make sure my baby was doing well enough for the procedure. During the ultrasound, the ultrasound tech a...
Source: Kidney Cancer Association - March 18, 2019 Category: Urology & Nephrology Source Type: news

Dr. Marc-Oliver Grimm provided an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session
In this article, Dr. Marc-Oliver Grimm provides an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session.03/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 18, 2019 Category: Urology & Nephrology Source Type: news

Antibiotics Before Checkpoint Inhibitors Tied to Worse Survival
Use of broad-spectrum antibiotics 30 days before starting an immune checkpoint inhibitor was associated with a dramatic reduction in cancer patients' survival, a prospective study found.03/11/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 11, 2019 Category: Urology & Nephrology Source Type: news

Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer
The treatment of metastatic clear cell renal cancer is changing rapidly, with the focus switching from vascular endothelial growth factor-targeted therapies to immune checkpoint inhibitors and novel combinations.03/07/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 7, 2019 Category: Urology & Nephrology Source Type: news

Toxicity, Clinical Outcomes of Varying Cabozantinib Dosage in Metastatic RCC
While clinical outcomes may be comparable in patients with metastatic renal cell carcinoma (RCC) who are treated with full vs reduced dose of cabozantinib, reduced dose may not be associated with decreased adverse events.03/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 6, 2019 Category: Urology & Nephrology Source Type: news

Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients
This study investigates its clinicopathologic characteristics and outcomes at a national level.03/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 5, 2019 Category: Urology & Nephrology Source Type: news

A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma
This study aims to investigate the gene expression changes in papillary renal cell carcinoma(pRCC) and screen several genes and associated pathways of papillary renal cell carcinoma progression.03/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 5, 2019 Category: Urology & Nephrology Source Type: news

Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses phase III findings on a comparison of tivozanib and sorafenib in patients with refractory advanced renal cell carcinoma03/04/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 4, 2019 Category: Urology & Nephrology Source Type: news

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses current models used to estimate the risk of recurrence of kidney cancer.02/27/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 27, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: When to Obtain Genetic Testing for Syndromic Renal Cell Cancer
Dr. Brian Schuch weighs in on genetic testing for kidney cancer.02/26/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 26, 2019 Category: Urology & Nephrology Source Type: news

Top Medications Used to Treat Kidney (Renal Cell Cancer)
This article discusses the top medications used to treat kidney cancer.02/25/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 25, 2019 Category: Urology & Nephrology Source Type: news

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non –clear cell renal cell carcinoma (RCC).02/20/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 20, 2019 Category: Urology & Nephrology Source Type: news

New therapeutic target found for aggressive pediatric cancers with few treatment options
Researchers at the University of Texas MD Anderson Cancer Center recently discovered a new therapeutic target for malignant rhabdoid tumors (MRT). MRT is a rare pediatric cancer that commonly starts in the kidneys. Dr. Pavlos Msaouel, who was a 2017 Conquer Cancer Foundation Young Investigator Award recipient supported by the Kidney Cancer Association, was involved in this breakthrough finding.02/19/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC.02/19/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma
During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Duran presented on the analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news

ASCO GU 2019: Genetic Evolution of Metastatic Renal Cell Cancer
At ASCO GU in San Francisco, Dr. Samra Turajlic discussed the evolution of metastatic renal cell carcinoma.02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news

Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU
Merck announced yesterday that new combination and monotherapy data from the company ’s broad immuno-oncology research program in genitourinary cancers – renal, prostate and bladder − will be presented at the 2019 Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 14-16.02/12/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 12, 2019 Category: Urology & Nephrology Source Type: news

Aerobics, Strength Exercises Improve Quality of Life in Kidney Cancer Survivors
Meeting combined exercise guidelines – including both aerobics and strength training – improved quality of life in #KidneyCancer survivors; however, few individuals reported they follow such guidelines, according to study findings published in Psycho-Oncology.02/12/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 12, 2019 Category: Urology & Nephrology Source Type: news

Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer
Nephron-sparing surgery (NSS) remains gold standard for the treatment of localised renal cell cancer (RCC), even in the case of a normal contralateral kidney.02/08/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 8, 2019 Category: Urology & Nephrology Source Type: news

Comparative study of renal cell carcinoma in patients less than 40 years of age and older age patients: A retrospective single-center study
Renal cell carcinoma (RCC) is typically found in the older age group between 50 and 70 years of age. However, diagnosis of renal cancer is increasing more rapidly in patients less than 40 years if age compared to older age patients.02/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 6, 2019 Category: Urology & Nephrology Source Type: news

Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study
Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop.02/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 6, 2019 Category: Urology & Nephrology Source Type: news

If Someone in Your Life Just Survived Cancer, Here ’s How You Can Support Them Now
This article explains how to support a loved one after cancer treatment.02/05/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 5, 2019 Category: Urology & Nephrology Source Type: news

Newsmakers: Promotions and appointments of area executives
Gretchen Vaughan, Kidney Cancer Association, has been named chief executive officer of the nonprofit.02/04/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 4, 2019 Category: Urology & Nephrology Source Type: news

Some Cancers Are Rising in Millennials. Obesity Might Be Why
Kidney cancer had the sharpest annual increase for young Americans: 6.23% between 1995 and 2014.02/04/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 4, 2019 Category: Urology & Nephrology Source Type: news

First-Line TKIs Less Effective in Non-Clear-Cell Renal Cell Carcinoma
According to a study that was published in Urologic Oncology, patients with metastatic non-clear-cell renal cell carcinoma (nccRCC) have worse outcomes from first-line therapy with tyrosine kinase inhibitors (TKIs) than patients with metastatic clear-cell RCC (ccRCC).01/31/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 31, 2019 Category: Urology & Nephrology Source Type: news

Personalized Vaccine to be Tested in Patients with Kidney Cancer
Researchers at the Dana-Farber Cancer Institute are working to develop a vaccine for the treatment of renal cell cancer.01/30/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 30, 2019 Category: Urology & Nephrology Source Type: news

The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial
Sunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient.01/29/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2019 Category: Urology & Nephrology Source Type: news

Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer
This study evaluates whether sunitinib and pazopanib treatments are associated with change in skeletal muscle area (SMA) and total lean body mass (LBM) as well as to compare their efficacies and safety profiles in patients with metastatic renal cell cancer (mRCC).01/29/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2019 Category: Urology & Nephrology Source Type: news

Personalised treatment benefits kidney cancer patients
Personalised treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsening kidney disease, according to a new study published in the journal Radiology.01/29/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 29, 2019 Category: Urology & Nephrology Source Type: news

Obesity Factors May Increase Kidney Cancer Risk
According to recent research conducted by Spectrum Health, certain factors such as diastolic blood pressure and fasting insulin were found to be associated with renal cell carcinoma.01/28/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 28, 2019 Category: Urology & Nephrology Source Type: news

Imaging Advances in the Management of Kidney Cancer
New developments in cross-sectional imaging, including contrast-enhanced ultrasound, dual-energy computed tomography, multiparametric magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography, together with novel application of existing and novel radiotracers, have changed the landscape of renal mass characterization (ie, virtual biopsy) as well as the detection of metastatic disease, prognostication, and response assessment in patients with advanced kidney cancer.01/25/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 25, 2019 Category: Urology & Nephrology Source Type: news

Kidney Cancer Association Appoints Gretchen Vaughan as CEO
HOUSTON– January 24, 2019– Kidney Cancer Association is pleased to announce it has recently appointed Gretchen Vaughan as the nonprofit’s new CEO. Vaughan brings more than 27 years of experience in advanced fundraising, management, sales and major market business development in the healthcare and financial service industries. Vaughan has most recently worked as the senior director of philanthropic resources with The University of Texas MD Anderson Cancer Center, having been with the hospital in additional, previous roles since 2004. Her work with MD Anderson includes extensive fundraising and philant...
Source: Kidney Cancer Association - January 25, 2019 Category: Urology & Nephrology Source Type: news

Cutaneous metastasis of renal cell carcinoma: Fine needle aspiration provides rapid diagnosis
The diagnosis of cutaneous metastasis of renal cell carcinoma is challenging in a young person in absence of a prior history of cancer. In such situation, fine needle aspiration alone as a minimally invasive procedure can provide rapid, accurate and cost effective diagnosis, even in case of unknown primary.01/23/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 23, 2019 Category: Urology & Nephrology Source Type: news

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma.01/23/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 23, 2019 Category: Urology & Nephrology Source Type: news

Ten-Year Outcomes of Renal Tumor Radio Frequency Ablation
According to a study that was published by the Journal of Urology, a total of 112 tumors in 106 patients were treated with radio frequency ablation. The median followup was 79 months (IQR 28.9-121.1) and mean ± SD tumor size was 2.5 ± 0.8 cm. Initial technical success was achieved in 97 percent of cases.01/23/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 23, 2019 Category: Urology & Nephrology Source Type: news

Personalized treatment benefits kidney cancer patients
Personalized treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsening kidney disease, according to a new study published in the journal Radiology.01/16/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 16, 2019 Category: Urology & Nephrology Source Type: news

Immunotherapy/VEGF Inhibitor Combos to Define Frontline Standard in mRCC
VEGF TKIs have long defined the frontline standard of care in metastatic renal cell carcinoma (mRCC), but several promising trials evaluating their use in combination with immunotherapy agents may redefine the frontline setting in this patient population.01/15/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2019 Category: Urology & Nephrology Source Type: news

European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Yesterday, Bristol-Myers Squibb announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ( “low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).01/15/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 15, 2019 Category: Urology & Nephrology Source Type: news

Royal Jelly May Ease Adverse Effects of RCC Drug Therapy
Royal jelly, a substance secreted by worker honeybees that is the exclusive food for queen bees, may ease the adverse effects of tyrosine kinase inhibitor (TKI) therapy for advanced renal cell carcinoma (RCC).01/11/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 11, 2019 Category: Urology & Nephrology Source Type: news

New breath test for cancer currently under trial
A clinical trial in the U.K. has just launched to assess the effectiveness of a newly developed breath test that could help diagnose multiple forms of cancer, including kidney cancer.01/09/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 9, 2019 Category: Urology & Nephrology Source Type: news

US cancer death rate hits 25 years of decline, study says
The rate of people dying from cancer in the United States seems to have dropped steadily for 25 years, a new study says, but disparities remain between the rich and the poor. The overall nationwide cancer death rate fell continuously from 1991 to 2016 by a total of 27%, according to a study by the American Cancer Society, published Tuesday in CA: A Cancer Journal for Clinicians.01/08/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 8, 2019 Category: Urology & Nephrology Source Type: news

Clinical Trials to Treat Kidney (Renal Cell) Cancer
Looking to enroll in a clinical trial? Check out this list from the National Cancer Institute.01/08/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 8, 2019 Category: Urology & Nephrology Source Type: news

Biological Cartographers Seek To Map The Trillions Of Cells In The Human Body
There's an effort underway to make a new atlas of all the cells in the human body and to describe each cell type using all the powerful tools of today's genetic technology. The study will take quite a few years to complete but scientists say the payoff will be huge. Through this study, they are hoping to gain new insights into many different diseases such as cancer.01/07/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 7, 2019 Category: Urology & Nephrology Source Type: news

Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma
This study discusses stereotactic radiosurgery for multiple brain metastases from renal-cell carcinoma.01/04/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 4, 2019 Category: Urology & Nephrology Source Type: news

Some RCC Risk Factors Can Be Modified
Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study that was done by the University of Texas Health Science Center and the South Texas Veterans Healthcare System.01/03/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 3, 2019 Category: Urology & Nephrology Source Type: news

A healthy organic diet reduces the risk of cancer by 65 percent
A recent study found that a healthy diet can reduce the risk of cancer by up to 65 percent.01/02/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 2, 2019 Category: Urology & Nephrology Source Type: news

Kidney Stones Up Kidney Cancer Risk
According to investigators, kidney stones are associated with an increased risk of papillary renal cell carcinoma (RCC) and upper tract urothelial carcinoma (UTUC).01/02/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 2, 2019 Category: Urology & Nephrology Source Type: news

MSKCC Risk Stratification Model in RCC Updated to Include Genomic Information
The Memorial Sloan Kettering Cancer Center (MSKCC) risk stratification model in advanced renal cell carcinoma (RCC) currently used in clinical practice stratifies patients into risk groups of favorable, intermediate, and poor.12/28/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 28, 2018 Category: Urology & Nephrology Source Type: news

Clinicopathological Features and Survival Data of Localized Renal Masses in Young Adults
According to a study that was done by the Asian Pacific Journal of Cancer Prevention, the overall survival rate of young adults (ages 18-40 years old) with localized renal masses is 93.8%.12/26/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 27, 2018 Category: Urology & Nephrology Source Type: news